|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1/IgG2a|
|Immunogen||T lymphocytes activated by mixed lymphocyte culture|
|Conjugate||FITC , PE|
|Storage buffer||PBS with 0.2% carrier protein|
|Contains||0.08% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is a monoclonal mixture of FITC-conjugated CD2 (clone T6.3, isotype IgG2a) and PE-conjugated CD19 (clone 1G9, isotype IgG1).
FITC excitation/emission is 494/518 nm; PE excitation/emission is 480+545+565/478 nm.
CD2 is found on the majority of human T and NK cells. CD2 presents on 78+8% normal peripheral lymphocytes and 100% of thymocytes. This antibody mixture detects CD2 antigen CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation. It is expressed in all B cell precursor leukemias.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.